Pentadeca Arginate (PDA) Research: What 0 Studies Show (2026) | RetatrutideCompare

Pentadeca Arginate (PDA) — 0 studies indexed on PubMed. Same as BPC-157 — angiogenesis, growth-factor modulation, tendon/GI healing in animal models. Half-life: Comparable to BPC-157 acetate. FDA status: Not FDA-approved; same regulatory status as BPC-157.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Pentadeca Arginate (PDA)?

There are approximately 0 studies indexed on PubMed that mention Pentadeca Arginate (PDA) (BPC-157 Arginate Salt, PDA), based on a search last updated 2026-06-18.

Is Pentadeca Arginate (PDA) FDA-approved?

FDA status: Not FDA-approved; same regulatory status as BPC-157.

How does Pentadeca Arginate (PDA) work?

Same as BPC-157 — angiogenesis, growth-factor modulation, tendon/GI healing in animal models.

Reference facts

Also known as: BPC-157 Arginate Salt, PDA
Category: Healing & Tissue Repair
Mechanism of action: Same as BPC-157 — angiogenesis, growth-factor modulation, tendon/GI healing in animal models.
Targets: Same as BPC-157
Indications under research or approved: Research only
Regulatory status (reference entry): Not FDA-approved; same regulatory status as BPC-157
Half-life: Comparable to BPC-157 acetate
Sequence: GEPPPGKPADDAGLV
Sequence notes: BPC-157 backbone (15-residue, 'pentadeca') as the arginate salt — promoted as more stable in solution than the acetate.
Molecular weight (Da): 1419
First reported: 2023

Primary References

Sikiric et al., Curr Pharm Des 2014

Explore research articles about Pentadeca Arginate (PDA)

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.